Siemens Healthineers Ag · XETR:SHL
Siemens Healthineers — Investor Day (December 2023)
38 slides from Siemens Healthineers's investor day presentation, Dec 7, 2023
Slide 1: Meet the Management 2023 Segment Presentations
Meet the Management 2023 Segment Presentations December 7, 2023 Unrestricted © Siemens Healthineers 2023
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be
Slide 3: Imaging
Imaging Meet the Management December 7, 2023 André Hartung Christian Klaussner Head of Imaging Finance Head of Imaging Meet the Management | Imaging 3 Unrestricted Unrestricted © Siemens Healthineers, 2023
Slide 4: The global leader in imaging – going from strength to strength
The global leader in imaging – going from strength to strength Successful growth engine is running at full steam 37% 1 FY2024E market share 1 ~75% revenue from Revenue innovations 2 growth 6% to 8% >€900m Sustainable industry-leading Value R&D invest 3 Creation 22% Adj. EBIT 21.0% to 22.5% industry-
Slide 5: The world needs Imaging
The world needs Imaging Fueled by mega trends Substantial untapped potential Ever-growing clinical value World’s population grows to ~10bn by 2050 1 >65% of low-income countries Alzheimer treatments emerge; with poor access to imaging 4 patients double to 110m in 20 yrs. 6 x2 People aged ≥60 Network
Slide 6: By 2030 all new MRI scanners will be helium-free, intelligent and everywhere
By 2030 all new MRI scanners will be helium-free, intelligent and everywhere Helium-free 1 & sustainable Intelligent & autonomous Everywhere Access to care: >65% of MAGNETOM 1.5T 3T >70% Free. systems sold in 0.55T faster 2 new markets 3 New customer groups: Conventional Deep Resolve Orthopedics, ve
Slide 7: We are years ahead leading the mega-trend of CT Photon-counting
We are years ahead leading the mega-trend of CT Photon-counting Years ahead Unrivaled clinical impact Unstoppable… NAEOTOM Alpha Introduce photon-counting to high-end Expand to own installed base FDA: «First Major Imaging (>35k devices) Device Advancement for Computed Tomography in Nearly a Decade»
Slide 8: Unmatched AI capabilities along every step of the smart imaging value chain
Unmatched AI capabilities along every step of the smart imaging value chain AI-enabled scanning AI-enabled reading & reporting AI-treatment Strong footprint in Imaging AI AI-Rad Companion AI-Rad Companion FAST 3D Camera Deep Resolve Chest CT Syngo Carbon Organs RT Author | Department 10 Restricted ©
Slide 9: RSNA: We are pioneering breakthroughs in healthcare
RSNA: We are pioneering breakthroughs in healthcare. For everyone. Everywhere. Sustainably. >37,000 attendees MAGNETOM Free.Max SOMATOM Pro.Pulse MAMMOMAT B.brilliant Syngo Carbon Unlock Dual Source CT. Everywhere Accurate and fast cancer detection Enterprise Imaging IT Meet the Management | Imaging
Slide 10: Value Partnerships leverage the full breadth and depth of Siemens Healthineers portfolio
Value Partnerships leverage the full breadth and depth of Siemens Healthineers portfolio Customers Partnership Value Value Partnerships Integrate oncology services, 10-year strategic partnership optimize the utilization of driving access to care diagnostic imaging equipment Health system covering fo
Slide 11: Continuing industry-leading growth and margins in Imaging
Continuing industry-leading growth and margins in Imaging Leveraging the power of our unique, Trajectory beyond 2025 synergistic portfolio and capabilities Winning together Comp. revenue growth At least mid- single-digit Continued margin Adj. EBIT margin expansion from scale Imaging, Varian, Advance
Slide 12: We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.
We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Meet the Management | Imaging 12 Unrestricted © Siemens Healthineers, 2023
Slide 13: Diagnostics
Diagnostics Meet the Management December 7, 2023 Sharon Bracken Michael Bueker Head of Diagnostics Finance Head of Diagnostics Meet the Management | Diagnostics 13 Unrestricted © Siemens Healthineers, 2023
Slide 14: Diagnostics delivers highly efficient testing at scale from the Core Lab to the Point-of-Care
Diagnostics delivers highly efficient testing at scale from the Core Lab to the Point-of-Care Revenue Split FY20231 Financials FY2023 Revenue Core (ex antigen) FY2024E Lab Legacy Atellica €1.1bn €1.1bn €1.1bn €1.2bn Revenue growth 2 to 4% Q1 Q2 Q3 Q4 (ex antigen) Adjusted EBIT Margin (ex antigen) 2%
Slide 15: Our transformation is progressing to plan
Our transformation is progressing to plan Transformation Financials Transformation Components FY2023 FY2024+ Supply Chain Capacity adjustments towards target Further capacity adjustments, and R&D portfolio manufacturing and distribution network optimization €300m Delayering and organizational Optimi
Slide 16: Our platforms are well positioned in attractive market segments
Our platforms are well positioned in attractive market segments Core Lab Solutions Specialty Lab Solutions Point of Care ✓€24bn global market ✓€9bn global market ✓€3bn global market Market Segment €24bn opportunity with +2.5% opportunity with +3% opportunity with +3% Attractiveness1 segment outlook
Slide 17: Growth driven by several sources across three Diagnostics Business Lines
Growth driven by several sources across three Diagnostics Business Lines Illustrative Diagnostics Revenue Development by Business Line 1 Diagnostics Comp Revenue Growth2 Above Market Average Strong growth in Atellica Portfolio offerings -1.2% 2 to 4% 3 to 5% Comp Revenue Growth to outpace exit of le
Slide 18: Crystalizing full potential of growth and profitability
Crystalizing full potential of growth and profitability Trajectory beyond 2025 Transforming to win Comp. revenue growth At least market rate Advancing to Adj. EBIT margin mid teens Diagnostics Creating value Meet the Management | Diagnostics 18 Unrestricted © Siemens Healthineers, 2023
Slide 19: We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.
We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Meet the Management | Diagnostics 19 Unrestricted Unrestricted © Siemens Healthineers, 2023
Slide 20: Varian
Varian Meet the Management December 7, 2023 Arthur Kaindl Matthias Platsch Head of Varian Finance Head of Varian Meet the Management | Varian 20 Unrestricted Confidential © Siemens Healthineers, 2023
Slide 21: The global leader in radiation oncology – with significant growth opportunities in comprehensive cancer care
The global leader in radiation oncology – with significant growth opportunities in comprehensive cancer care 55%1 1 140k+ market share FY2024E software users with ~10k installed linacs across >5k generating >45% institutions recurring service revenue Revenue growth 8 to 10% +20% 35k+ unit growth y-o
Slide 22: Varian is uniquely equipped to address the rising global cancer burden and expand access to care
Varian is uniquely equipped to address the rising global cancer burden and expand access to care Global cancer burden is rising and 50-60% the gap in access is widening1 of all cancer patients2 benefit from radiation therapy = 500K = no access to care 30m new cases 20m new cases Global Market Reach
Slide 23: Varian is driving the integration of imaging and therapy across the cancer care continuum
Varian is driving the integration of imaging and therapy across the Comprehensive cancer Comprehensive Cancer care Care Care: :Chest continuum Cancer Chest Program to Example optimize Program Examplecare Comprehensive Cancer Care : Chest Program Example Engage Engage Engage patients patients Optimiz
Slide 24: Varian is innovating through combining imaging and therapy with digital solutions and services
Varian is innovating through combining imaging and therapy with digital solutions and services HyperSight RapidArc Dynamic Ultra-fast and precise Accelaration of radiotherapy Cone-Beam CT for by intelligent dose modulation adaptive radiation therapy Digitally-Enabled Clinical Services Interventional
Slide 25: Varian and Nova Scotia Health Collaborating to transform cancer care
Varian and Nova Scotia Health Collaborating to transform cancer care “Together with Varian, we‘re not just witnessing change, we are steering it. Each advancement in cancer care is a crucial step in our long-term plan to transform care delivery in Nova Scotia, and we can‘t do it without Varian.” Hon
Slide 26: Varian will drive margin improvements from multiple sources
Varian will drive margin improvements from multiple sources Advancing towards Imaging-like margin levels Productivity Pricing Conversion ▪ Process optimization through ▪ Full realization of pricing ▪ Above-market growth in best practice sharing measures radiotherapy ▪ Leveraging in-house ▪ High-marg
Slide 27: Varian continuing strong growth and expanding margins in the winning combination
Varian continuing strong growth and expanding margins in the winning combination Leveraging the power of our unique, Trajectory beyond 2025 synergistic portfolio and capabilities Winning together Comp. revenue growth At least high- single-digit Advancing towards Adj. EBIT margin Imaging-like margins
Slide 28: We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.
We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Meet the Management | Varian 28 Unrestricted Confidential © Siemens Healthineers, 2023
Slide 29: Advanced Therapies
Advanced Therapies Meet the Management December 7, 2023 Carsten Bertram Stephan Müller Head of Finance Head of Advanced Therapies Advanced Therapies Meet the Management | Advanced Therapies 29 Unrestricted Unrestricted © Siemens Healthineers, 2023
Slide 30: Advanced Therapies: leading in image guidance – significant growth opportunities in minimal invasive procedures
Advanced Therapies: leading in image guidance – significant growth opportunities in minimal invasive procedures Market position Revenue FY2023 FY 2024E 32% €2.0 bn Comp. Market Share 1 Mobile C-Arms revenue 5 – 8% 20% growth ~49 k Installed base 2 Adj. EBIT > 10% 80% Angiography margin 15 – 17% Syst
Slide 31: We grow our business leveraging global trends and pioneering innovations in image guidance
We grow our business leveraging global trends and pioneering innovations in image guidance for fast growing procedures Our business is driven by We pioneer minimally invasive Our focus ensures global trends therapy solutions continuous growth Growing and aging population Precision We address the mos
Slide 32: As pioneers in minimally invasive treatments, we address the most threatening diseases
As pioneers in minimally invasive treatments, we address the most threatening diseases and most relevant procedures globally Continuous shift to minimally invasive procedures … … with high growth in multiple clinical segments1 Cardiovascular Care 12% Growth in structural heart disease Neurovascular
Slide 33: Innovations & partnerships drive our growth in interventional therapies
Innovations & partnerships drive our growth in interventional therapies. The world innovates for – and with – us! Siemens Healthineers Innovation in Image Guidance, AI & Robotics Rapid growth in number of procedures Full potential of interventional therapies Device Companies Innovation in Paradigm s
Slide 34: We open new horizons by innovating image guidance for fixed and mobile C-arms
We open new horizons by innovating image guidance for fixed and mobile C-arms ARTIS icono CIARTIC Move Next-gen image guidance 1st self-driving mobile C-arm 360° • Our unique platform to meet both clinical and business challenges • Our breakthrough for automated intraoperative 3D imaging for Interve
Slide 35: Innovation in stroke treatment – Providing cutting edge image guidance today
Innovation in stroke treatment – Providing cutting edge image guidance today; pioneering endovascular robotics for the future Clinical need1 Our solutions ARTIS icono Endovascular Robotics Cutting-edge image guidance Robotic platform for neurovascular procedures2 In development • Stroke is the #2 ca
Slide 36: Our Innovations & Partnerships create value for our customers
Our Innovations & Partnerships create value for our customers, while growing revenue and profitability for Advanced Therapies Driving Growth in a dynamic and fast-growing market … with breakthrough innovations … together with strong … leveraging the unique, synergetic … to improve clinical outcomes
Slide 37: Continuing growth and expanding margins in Advanced Therapies
Continuing growth and expanding margins in Advanced Therapies Leveraging the power of our unique, Trajectory beyond 2025 synergistic portfolio and capabilities Winning together Comp. revenue growth At least mid- single-digit Returning to industry- Adj. EBIT margin leading levels Imaging, Varian, Adv
Slide 38: We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.
We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Meet the Management | Advanced Therapies Unrestricted Unrestricted © Siemens Healthineers, 2023